15th Annual eyeforpharma Barcelona 2017

14 - 16 March 2017, Barcelona, Spain.
eyeforpharma Barcelona is Europe's largest commercial pharma meeting of 1000+ industry leaders focused on commercial innovation, engagement strategy, patient centricity and stakeholder collaboration.

1000+ delegates, 80+ senior level speakers, 6 key themes - find out more here.

Speakers include:

  • Richard Francis, CEO, Sandoz
  • Esteban Plata, President International, Western Europe & Canada, AbbVie
  • Greg Behar, CEO, Nestlé Health Science
  • Gitte Aabo, CEO, LEO Pharma
  • Brian Otis, CTO, Verily (Google Life Sciences)

Why Barcelona?

  • Collaborative setting: Our aim is to ensure your key stakeholders are present to advance partnerships with healthcare, technology, patients and patient associations
  • An inspiring agenda: As you undergo a commercial evolution we will cover 6 key themes, provide intimate workshops and keynote sessions to help direct your journey
  • 1000+ in attendance: If you are looking for one commercial meeting to attend in 2017, Barcelona will be sure to give you the most senior networking opportunities possible

World Pharma News readers can benefit from an exclusive discount - save €200 using our unique discount code WPN200 when you register online.

For more information and to reserve your pass, visit the Barcelona website.

About eyeforpharma
Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry’s health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the center.

Most Popular Now

New analysis shows Novartis Entresto improves glyc…

Novartis has announced results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF) and diabetes suggesting that Entr...

Read more

Mutual Recognition promises new framework for phar…

The United States and the European Union (EU) completed an exchange of letters to amend the Pharmaceutical Annex to the 1998 U.S.-EU Mutual Recognition Agreement. Under t...

Read more

Potential drug candidates halt prostate and breast…

Scientists on the Florida campus of The Scripps Research Institute (TSRI) have designed two new drug candidates to target prostate and triple negative breast cancers. The...

Read more

Novartis' Cosentyx shows almost all psoriasis pati…

Novartis has announced a new analysis showing that moderate-to-severe psoriasis patients treated with Cosentyx® (secukinumab) rapidly regain clear or almost clear skin (P...

Read more

Scientists stimulate immune system, stop cancer gr…

Researchers at the University of Illinois at Chicago report that increasing expression of a chemical cytokine called LIGHT in mice with colon cancer activated the immune ...

Read more

Johnson & Johnson completes acquisition of Abb…

Johnson & Johnson (NYSE: JNJ) has completed the acquisition of Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott. The all-cash $4.325 billion acquisition w...

Read more

New England Journal of Medicine publishes long-ter…

In 2001 the U.S. Food and Drug Administration granted priority review for imatinib mesylate, sold under the name Gleevec®*, as an oral therapy for patients with chronic m...

Read more

Bristol-Myers Squibb expands focus on precision me…

Bristol-Myers Squibb Company (NYSE: BMY) announced its equity investment and plans for a research collaboration with GRAIL Inc., a life sciences company whose mission is ...

Read more

Volkswagen's excess emissions will lead to 1,200 p…

In September 2015, the German Volkswagen Group, the world's largest car producer, admitted to having installed "defeat devices" in 11 million diesel cars sold worldwide b...

Read more

MedImmune and Sanofi Pasteur form alliance to deve…

MedImmune, the global biologics research and development arm of AstraZeneca, and Sanofi Pasteur, the vaccines division of Sanofi, have announced an agreement to develop a...

Read more

Cooking at home tonight? It's likely cheaper and h…

Researchers from the University of Washington School of Public Health have been peeking into kitchens - via interviews - for years now. They've just published results sho...

Read more

Human antibody for Zika virus promising for treatm…

Researchers have determined the structure of a human antibody bound to the Zika virus, revealing details about how the antibody interferes with the infection mechanism - ...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]